Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of Velcade with gemcitabine and cisplatin in advanced non-small cell lung cancer
2006-004963-68Phase 2Completed
- Sponsor
- Prof Vassilis Georgoulias
- Start
- May 2007
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Prof Vassilis Georgoulias. Primary endpoints: Objective response rate and Safety. Started May 2007; status: completed.
02
Drugs
bortezomibgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004963-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004963-68.